Special Issue

State of the Art in Pathogenesis and Targeted Therapy in Chronic Obstructive Pulmonary Disease

Message from the Guest Editor

This Special Issue will delve into the latest advances in understanding the pathogenesis of COPD and innovative approaches to its targeted therapy. It will cover a broad spectrum of topics, including, but not limited to, the molecular and genetic underpinnings of COPD, the role of inflammation in disease progression, novel biomarkers for diagnosis and prognosis, and the latest developments in treatment, mostly focused on targeted therapies. Furthermore, it will explore emerging trends in personalized medicine for COPD, novel drug delivery systems, and the challenges and barriers in translating research findings into clinical practice. Ultimately, this Special Issue will inspire further research and improve patient outcomes by advancing both scientific knowledge and clinical practice in COPD management.

Guest Editor

Dr. Emanuela Tudorache

Center for Research and Innovation in Precision Medicine of Respiratory Diseases, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania

Deadline for manuscript submissions

30 August 2026



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/229028

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpl.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

